title: Extended release once a day tacrolimus.
abstract: OBJECTIVE
  This article provides an update of the literature on the use of extended release once-daily tacrolimus in solid organ transplant recipients.
  
  
  RESULTS
  Medication nonadherence occurs in a substantial proportion of patients posttransplant and is associated with worse outcomes. Multiple daily dosing is associated with an increased risk for nonadherence. Several studies have indicated once-daily dosing of medications and reduced complexity improve medication adherence. The extended release formulations of tacrolimus have been developed with the potential benefits of improving adherence, and hence safety and outcomes. Astagraf XL™ (Advagraf in Europe) and Envarsus XR. are the two extended release once-daily tacrolimus formulations that have recently become available for clinical use and provide promising alternatives to the treatment choices available for immunosuppression in solid organ transplant recipients.
  
  
  CONCLUSIONS
  Although extended release tacrolimus shows promise in improving patient adherence to transplant medication therapy, further studies are needed to confirm improved compliance and to assess long-term safety and efficacy.
authors.affiliation: aDivision of Nephrology and Hypertension, Department of Internal Medicine, LSU Health Shreveport School of Medicine, Shreveport, Louisiana bDivision of Nephrology, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio cDivision of Nephrology, Department of Internal Medicine, State University of New York at Buffalo, Buffalo, New York, USA.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Singh
authors.forename: Jon
authors.initials: J
authors.lastname: Von Visger
authors.forename: Mareena
authors.initials: M
authors.lastname: Zachariah
mesh_terms: D064591:Allografts; D006084:Graft Rejection / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016377:Organ Transplantation; D012307:Risk Factors; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus